OncoResponse is a clinical stage, privately held immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. The company’s lead candidate, OR2805, has entered clinical studies with a unique and transformative approach to the advancement of cancer therapeutics. OncoResponse is based in Seattle, Washington.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $27M
Founded date: 2016
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.05.2023 | Grant | $27M | Takeda Ven... |
Mentions in press and media 3
| Date | Title | Description |
| 23.06.2023 | New app rolls through hundreds of local stories for road trippers traversing Texas | There's almost no better education on the state of Texas than driving through it — almost. The only thing better would be listening to stories about Texas history on that drive. A GPS-based entertainment app, Autio (currently only available... |
| 13.06.2023 | Seattle biotech co. to move to Houston thanks to $13.3M grant from Texas organization | A biotech company has landed a more than $13 million grant from the Cancer Prevention and Research Institute of Texas. The nearly $13.3 million grant given to OncoResponse — which is relocating from Seattle to Houston, according to CPRIT's ... |
| 18.05.2023 | OncoResponse Raises $14M; Awarded $13M in Funding | OncoResponse, a Seattle, WA-based clinical-stage biotech company, raised $14M in funding. The round was led by RiverVest Venture Partners and including ARCH Venture Partners, Canaan Partners, 3B Future Health Fund, Bering Capital, Takeda Ve... |